ERA 2026 Preview: Competitive Shifts in Nephrology
ERA 2026 at a glance ERA 2026 highlights emerging competitive developments in…
Lucid Diligence Brief: R1 Therapeutics $77.5 million Series A to treat hyperphosphatemia in CKD dialysis
Lucid Diligence Brief: R1 Therapeutics $77.5 million Series A to treat…

